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Background: Diffuse malignant peritoneal mesothelioma and ocular melanoma are both rare tumors. To the best
of our knowledge there is only one previous report of three cases in a family with known susceptibility to
malignancies associating diffuse malignant peritoneal mesothelioma and ocular melanoma, with no sporadic cases
previously reported.
Case presentation: We describe the case of a 59-year-old man with a history of diffuse malignant peritoneal
mesothelioma, who presented with ocular melanoma 41 months after cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy. We also briefly review the literature.
Conclusions: Diffuse malignant peritoneal mesothelioma is an uncommon but aggressive disease. As diffuse
malignant peritoneal mesothelioma characteristically remains confined to the abdominal cavity, any new
extra-abdominal symptom should eventually raise suspicion of another primary tumor. Few cases of diffuse
malignant peritoneal mesothelioma associated with other primary tumors have been reported. As ocular melanoma
is also infrequent, we suspect a genetic predisposition to these tumors. There is emerging evidence supporting the
role of BAP1 mutations in the pathogenesis of these two neoplasias.
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Diffuse malignant peritoneal mesothelioma (DMPM) is a
rare but aggressive tumor arising from the serosal lining
of the peritoneal cavity. In industrialized countries, inci-
dence rates of DMPM range between 0.5 and 1.7 cases
per million in the general population [1]. Using trad-
itional treatment modalities such as systemic chemother-
apy and palliative surgery, median survival is poor
(about 12 months). For nearly a decade, a new approach
combining aggressive cytoreductive surgery (CRS) and
hyperthermic intraperitoneal chemotherapy (HIPEC) has
dramatically improved median survival, and this has
reached 5 years in some series [2].* Correspondence: lucas.sideris@umontreal.ca
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reproduction in any medium, provided the orWe present the case of a patient with DMPM initially
treated with this approach, who later developed ocular
melanoma (OM). Few other primary tumors have been
linked to DMPM. To the best of our knowledge there is
only one previous study reporting three patients with
DMPM and OM, all in the same family [3].Case presentation
A 59-year-old man sought medical attention in 2005
for vague abdominal discomfort, nausea and belching
that had started 6 months earlier. The patient did not
have any previous history of cancer in his family or
any history of asbestos exposure. He denied any other
gastrointestinal or constitutional symptoms. A physical
examination was unremarkable except for a slightly
distended abdomen. Initial investigations included routine
laboratory investigations, an upper gastrointestinal tract
endoscopy and a colonoscopy, all within normal limits.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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revealed omental caking, perihepatic ascites and neoplas-
tic seeding in Morrison’s pouch and the perihepatic space
(Figure 1). There was no evident lymphadenopathy
present. A single hepatic lesion was further investigated
by magnetic resonance imaging (MRI), which was com-
patible with a benign hemangioma. A staging investigation
was negative for extra-abdominal metastases. The patient
underwent diagnostic laparoscopy. Intraoperative findings
revealed an omental thickening with nodules on the
omentum and diffuse involvement of the peritoneal sur-
face with relative sparing of the liver, spleen, stomach, and
small and large intestine. Peritoneal biopsies results were
compatible with DMPM of the epithelial subtype. He was
then referred to our institution for definitive treatment. At
3 months after diagnostic laparoscopy, our team per-
formed a complete CRS and HIPEC. Total right diaphrag-
matic, partial left diaphragmatic (2/3), total pelvic and
parietal anterior peritonectomies were performed. The
CRS procedure also included cholecystectomy, splenec-
tomy, omentectomy, mesenteric implant fulguration and
removal of laparoscopic surgery trocar sites that were
invaded with tumor nodules. The peritoneal cancer index
(PCI) was 21 (maximal possible score: 39). This index
takes into account the number of invaded areas from a
total of 13, and the maximal size of tumors nodules within
3 possible groups (<5 mm, 5 mm to 5 cm, >5 cm) [4].
After CRS, there was no residual tumor (completeness of
cytoreduction (CCR) score= 0). HIPEC was performedFigure 1 Computed tomography (CT) scan of the abdomen.
This CT scan of the abdomen performed before cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) shows neoplastic involvement of trocar sites (red arrow) and
omentum (white arrow).with oxaliplatin 460 mg/m2 for 30 minutes and systemic
5-FU was simultaneously infused. The findings on the
final pathological report were as follows: multifocal and
multinodular tumor with numerous psammomatous calci-
fications, tumor made with polygonal cells showing a
tubulopapillary proliferation pattern, cells present on the
peritoneal surface and invading the underlying tissue in-
ducing desmoplasia, tumor cells of intermediate size with
a moderately abundant eosinophilic cytoplasm, round and
slightly irregular nuclei with prominent nucleoli, weak mi-
totic activity, no intracytoplasmic mucin on periodic acid-
Schiff diastase (PAS-D) staining. Immunohistochemical
studies have been performed for vimentin, keratin 5/6,
calretinin, Wilms' tumor 1 (WT1), carcinoembryonic
antigen (CEA), CD15, E cadherin, Ber-EP4 and CD141.
Tumor cells were extremely positive for calretinin,
keratin 5/6 and focally positive for CD141. In conclu-
sion, the histological aspect and the immunohisto-
chemistry confirmed the diagnosis of DMPM of epithelial
subtype.
Our patient’s postoperative course was complicated by
respiratory failure episodes (secondary to pleural effu-
sions and pulmonary edema), a right subphrenic abscess
and a lower limb deep venous thrombosis. Recovery was
slow but complete and our patient was discharged after
6 weeks. He was then followed with a positron emission
tomography-computed tomography (PET-CT) scan every
4 months for 1 year and then every 6 months. At 36
months after treatment (June 2009), a PET-CT scan
showed no evidence of recurrence.
In November 2009 (41 months after CRS and HIPEC),
the patient complained of blurred vision in his left eye and
was referred to an ophthalmologist. Fundoscopic examin-
ation of the left eye revealed a solid pigmented choroidal
mass above the macula measuring 6.9 × 9.2 mm in base
and 2.5 mm in height. The patient was then referred to a
medical oncology service for systemic staging. MRI of the
brain, and a CT scan of the thorax, abdomen and pelvis
did not show any evidence of metastatic disease. The med-
ical oncology team assumed that the left eye tumor was
metastatic disease from DMPM and external beam radio-
therapy of a total dose of 40 Gy (20 fractions of 2 Gy) was
administered. Further ophthalmologic assessment showed
no treatment response, the size of the tumor increased to
8.1× 11.3 mm in base and 2.9 mm in height. Two fine nee-
dle biopsies were performed but the results were deemed
inconclusive. A second ophthalmologic evaluation by a
specialized group of ocular oncologists was obtained.
On fundus examination, a choroidal melanocytic lesion su-
perior to the macular area was found. The lesion showed
different grades of pigmentation, orange pigment on its
surface and the presence of subretinal fluid (Figure 2).
B-scan ultrasound revealed an acoustically hollow dome-
shaped lesion (Figure 3), which on A-scan demonstrated a
Figure 2 Ocular fundus image of the choroidal melanoma.
Clinical appearance of the choroidal mass after receiving external
radiation therapy. A choroidal melanocytic lesion was found superior
to the macular area. Note the orange pigment, which is highly
suggestive of choroidal melanoma.
Figure 3 Ultrasound of the left eye. Combined A-scan and B-scan
ultrasound showing an acoustically hollow dome-shaped lesion,
which demonstrated a medium to low reflectivity, and a maximum
height of 3.15 mm.
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mm. Based on the clinical appearance and ancillary test-
ing, a diagnosis of ocular melanoma was supported.
In November 2010, brachytherapy with an iodine-125
plaque at a total dose of 80 Gy to the apex of the tumor
was performed. In October 2011 the tumor reduced in
size to 2.9 mm in height and there was no sign of recur-
rence of DMPM or OM on PET-CT.
Discussion
DMPM accounts for 30% of all malignant mesotheliomas
[5]. The median age at diagnosis is 65 to 69 years. Asbes-
tos exposure is the major risk factor for peritoneal meso-
thelioma even though association is less strong than for
pleural mesothelioma, especially in women. Infection by
the simian tumor virus (SV-40) and prior radiation expos-
ure may also play a role in pathogenesis of DMPM [6].
DMPM can be divided into three histologic subtypes: epi-
thelial (most common), sarcomatoid and biphasic (epithe-
lial and sarcomatoid components). Immunohistochemistry
is helpful to distinguish DMPM from other peritonealcancers (colorectal adenocarcinoma and ovarian carcinoma,
among others) [5]. Metastatic papillary adenocarcinoma
was the initial diagnosis in this case, which was later con-
firmed to be a DMPM by immunohistochemical studies.
Although there is no commonly accepted standard
of care for DMPM, it is well established that CRS and
HIPEC therapy has prolonged median survival: 12 months
with palliative surgery and/or systemic chemotherapy
versus nearly 5 years with CRS and HIPEC [2].
In the investigation of new symptoms in DMPM cases,
clinicians must recall that DMPM characteristically tend
to recur locally and therefore, extra-abdominal metastases
are uncommon. The hypothesis of another primary tumor
should be considered despite the few cases reported of
DMPM associated with primary malignancies, especially in
the context of lacking a history of asbestos exposure as in
our case. A series of 500 cases of DMPM reported a 1.8%
rate of DMPM associated with other primary tumors [7]. In
a multicenter study of 81 cases, a higher incidence (8.6%)
was reported [8]. Various types of cancer have been previ-
ously associated with DMPM (colorectal, breast, multiple
myeloma, bronchogenic and bladder carcinomas) but none
with a strong association [7-9].
Similar to DMPM, OM is an infrequent malignancy
with an estimated annual incidence of six cases per
million. It is the most common primary intraocular malig-
nancy in adults, with the choroid affected in 90% of cases
[10]. Known risk factors include fair skin, light-colored
eyes and the presence of pre-existing uveal nevus (our
patient has the two former features) [11]. Several genetic
mutations in chromosomes 3, 6 and 8 have also been
identified in association with OM [11]. Current treatment
includes brachytherapy for small and medium-sized
tumors, with enucleation reserved for large tumors [12].
An overall survival of 50% at 10 years is accepted.
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has been previously described in three cases in a family
with known susceptibility to malignancies. All cases were
found to have a BAP1 mutation [3]. BAP1 is a tumor sup-
pressor gene located on chromosome 3p21 and the BAP1
protein is involved in DNA damage response, regulation
of cell cycle and cell growth. Mutations in BAP1 are infre-
quent in the general population but high in mesothelioma
(20.1%) and uveal melanoma (44.1%) [13-15]. The joint
probability of the occurrence of both mesothelioma and
OM in the same individual by chance has been estimated
as 36 per trillion per year by Testa et al. [3] In that study,
the authors found germline BAP1 mutations in 2 of 26
patients diagnosed with mesothelioma and both patients
were previously diagnosed with uveal melanoma. Three of
their four patients with uveal melanoma and BAP1 muta-
tions subsequently developed mesothelioma. They have
suggested a new BAP1-related cancer syndrome charac-
terized by mesothelioma and ocular melanoma, and
possibly other malignancies [3]. In our patient, the
mesothelioma was the presenting malignancy and 41
months later a choroidal melanoma was diagnosed.
Clinicians should be aware of this entity since indivi-
duals who carry germline BAP1 mutations may be at
increased risk of developing metachronously both OM
and DMPM. Patients found with BAP1 mutations and
their families should be closely monitored for the de-
velopment of any or both of these malignancies for
the possibility of early detection and intervention.
Conclusions
Patients with DMPM who undergo CRS and HIPEC can
expect a longer life expectancy in comparison to patients
treated by other therapeutic modalities. Nevertheless,
the association of other primary cancer with DMPM
may complicate the management and alter the prognosis
for these patients.
To the best of our knowledge, this is the first
known case report of DMPM and OM occurring in
the same individual with no family history. This art-
icle is an important element to support the concept
of a clinical correlation between DMPM and OM,
probably as a BAP1-related cancer syndrome since
the probability of the occurrence of both malignancies
by chance in the same individual is extremely remote.
Genetic testing for BAP1 mutations in this patient
and his family is currently in progress and the results
will be the subject of another publication.
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